2008 standards, options: Recommendations for venous thromboembolic events (VTE) treatment and central venous catheter thrombosis (CVCT) management in cancer patients;Standards, options: Recommendations 2008: Traitement curatif de la maladie thromboembolique veineuse, prévention et traitement des thromboses veineuses sur cathéter chez les patients atteints de cancer

Bulletin du Cancer

Volumn 95, Issue 7-8, 2008, Pages 750-761

  Debourdeau, Philippe ^a   Farge Bancel, Dominique ^b   Bosquet, Lise ^c   Kassab Chahmi, Diana ^c   Cajfinger, Francis ^d   Desmurs Clavel, Hélène ^d   Desruennes, Éric ^e   Douard, Marie Cécile ^b   Elias, Antoine ^f   Elalamy, Ismail ^g   Grange, Claire ^h   Hocini, Hamid ^b   Kriegel, Iréne ⁱ   Le Gal, Grégoire ^j   Lévesque, Hervé ^k   Mahé, Isabelle ^l   Meyer, Guy ^m   Mismetti, Patrick ⁿ   Pavic, Michel ^a   Quéré, Isabelle ^o   Renaudin, Jean Marc ^m   Scrobohaci, Marie Lorraine ^b   more..

^a Servicc lie Pneumologie Hôpital d'lnstruction des Armées Desgenettes   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c INSTITUT NATIONAL DU CANCER   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Hopital Font Pre   (France)

^g HÔPITAL TENON   (France)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ INSTITUT CURIE   (France)

^j SERVICE DE RHUMATOLOGIE   (France)

^k Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^l HÔPITAL LOUIS MOURIER   (France)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁿ HÔPITAL NORD   (France)

^o HÔPITAL SAINT ELOI   (France)

more..

Author keywords

Cancer; Central venous catheter; Clinical practice guideline (CPG); Thrombosis; Venous thromboembolic events

Indexed keywords

ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; TINZAPARIN; WARFARIN; ANTICOAGULANT AGENT;

ARTICLE; BLEEDING; CANCER CENTER; CANCER PATIENT; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COOPERATION; EVIDENCE BASED PRACTICE; FRANCE; HEALTH CARE ORGANIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; PATIENT SELECTION; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; RECOMMENDED DRUG DOSE; TREATMENT OUTCOME; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; CATHETERIZATION; NEOPLASM; REVIEW;

ANTICOAGULANTS; CATHETERIZATION; FIBRINOLYTIC AGENTS; FRANCE; HEPARIN; HUMANS; NEOPLASMS; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM;

EID: 51349127706     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1648/bdc.2008.0678     Document Type: Article

References (89)

1. AGREE C. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12: 18-23.
2. Fervers B, Bonichon F, Demard F, Heron JF, Mathoulin S, Philip T, et al. Méthodologie de développement des Standards, Options et Recommandations diagnostiques et thérapeutiques en cancérologie. Bull Cancer 1995; 82: 761-7.
3. Fervers B, Hardy J, Blanc-Vincent MP, Theobald S, Bataillard A, Farsi F, et al. SOR: project methodology. Br J Cancer 2001; 84 Suppl 2: 8-16.
4. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
5. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine 2003; 349: 146-53.
6. Calligaro KD, Bergen WS, Haut MJ, Savarese RP, DeLaurentis DA. Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement. Annals of Vascular Surgery 1991; 5: 186-9.
7. Chan A, Woodruff RK. Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. Australian & New Zealand Journal of Medicine 1992; 22: 119-22.
8. Debourdeau P, Meyer G, Sayeg H, Marjanovic Z, Bastit L, Cabane J, et al. Traitement anticoagulant classique de la maladie thromboembolique veineuse chez les patients cancéreux. À propos d'une série rétrospective de 71 patients. Revue de Medecine Interne 1996; 17: 207-12.
9. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119: 1062-72.
10. Lensing AW, Prins MH, Davidson BL, Hirsh J, Lensing AW, Prins MH, et al. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. [see comment]. Arch Intern Med 1995; 155: 601-7.
11. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS, Siragusa S, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis.[see comment]. Am J Med 1996; 100: 269-77.
12. Hettiarachchi RJ, Prins MH, Lensing AW, Bullet HR. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism.[see comment]. Curr Opin Pulm Med 1998; 4: 220-5.
13. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM, Gould MK, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9.
14. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G, Dolovich LR, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 181-8.
15. Rocha E, Martinez-Gonzalez MA, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica 2000; 85: 935-42.
16. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140: 175-83.
17. Mismetti P, Quenet S, Levine M, Merli G, Decousus H, Derobert E, et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest 2005; 128: 2203-10.
18. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729-35.
19. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clinical & Applied Thrombosis/ Hemostasis 2006; 12: 389-96.
20. Bona RD, Hickey AD, Wallace DM. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. American Journal of Clinical Oncology 2000; 23: 71-3.
21. Palareti C, Legnani C, Lee A, Manotti C, Hirsh J, D'Angelo A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thrombosis & Haemostasis 2000; 84: 805-10.
22. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-8.
23. Vucic N, Ostojic R, Svircic T. Treatment of deep vein thrombosis with oral anticoagulants in patients with malignancy: prospective cohort study. Croatian Medical Journal 2002; 43: 296-300.
24. Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandala M, et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest 2006; 130: 1808-16.
25. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003; 1: 1906-13.
26. Noble SI, Finlay IG. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliative Medicine 2005; 19: 197-201.
27. Noble SI, Nelson A, Turner C, Finlay IG. Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study [Comment in: BMJ. 2006 Mar 25;332(7543):728-9. PMID: 16565137;Comment in: BMJ. 2006 Mar 25;332(7543):729. PMID: 16565142]. BMJ 2006; 332: 577-80.
28. Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer. American Heart Journal 1997; 134: 603-7.
29. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism [Comment in: J Clin Oncol. 2005 Apr 1;23(10):2119-20. PMID: 15699474;Comment in: J Clin Oncol. 2005 Oct 1;23(28):7248. PMID: 16192624;Comment in: J Clin Oncol. 2005 Oct 1;23(28):7248-50; author reply 7250. PMID: 16192623]. J Clin Oncol 2005; 23: 2123-9.
30. Cohen JR, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 1991; 109: 12-5.
31. Cohen JR, Grella L, Citron M. Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer. Cancer 1992; 70: 1993-6.
32. Hubbard KP, Roehm JO, Jr., Abbruzzese JL. The Bird's Nest Filter. An alternative to long-term oral anticoagulation in patients with advanced malignancies. Am J Clin Oncol 1994; 17: 115-7.
33. Schwarz RE, Marrero AM, Conlon KC, Burt M. Inferior vena cava filters in cancer patients: indications and outcome. Journal of Clinical Oncology 1996; 14: 652-7.
34. Greenfield LJ, Proctor MC, Saluja A. Clinical results of Greenfield filter use in patients with cancer. Cardiovascular Surgery 1997; 5: 145-9.
35. Ihnat DM, Mills JL, Hughes JD, Gentile AT, Berman SS, Westerband A. Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine? Journal of Vascular Surgery 1998; 28: 800-7.
36. Jarrett BP, Dougherty MJ, Calligaro KD. Inferior vena cava filters in malignant disease. Journal of Vascular Surgery 2002; 36: 704-7.
37. Wallace MJ, Jean JL, Gupta S, Eapen GA, Johnson MM, Ahrar K, et al. Use of inferior vena caval filters and survival in patients with malignancy. Cancer 2004; 101: 1902-7.
38. Zerati AE, Wolosker N, Yazbek G, Langer M, Nishinari K. Vena cava filters in cancer patients: experience with 50 patients. Clinics (Sao Paulo, Brazil) 2005; 60: 361-6.
39. Schunn C, Schunn GB, Hobbs G, Vona-Davis LC, Waheed U. Inferior vena cava filter placement in late-stage cancer. Vascular & Endovascular Surgery 2006; 40: 287-94.
40. Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983; 13: 334-6.
41. Dhami MS, Bona RD, Calogero JA, Hellman RM. Venous thromboembolism and high grade gliomas. Thromb Haemost 1993; 70: 393-6.
42. Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 1991; 68: 2621-4.
43. Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O'Fallon JR. Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 1994; 69: 329-32.
44. Valladares JB, Hankinson J. Incidence of lower extremity deep vein thrombosis in neurosurgical patients. Neurosurgery 1980; 6: 138-41.
45. Walsh DC, Kakkar AK. Thromboembolism in brain tumors. Curr Opin Pulm Med 2001; 7: 326-31.
46. Schmidt F, Faul C, Dichgans J, Weller M. Low molecular weight heparin for deep vein thrombosis in glioma patients. Journal of Neurology 2002; 249: 1409-12.
47. Altschuler E, Moosa H, Selker RG, Vertosick FT, Jr. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery 1990; 27: 74-6.
48. Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993; 43: 1111-4.
49. Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994; 73: 493-8.
50. Bern MM, Lokich JJ, Wallach SR, Bothe A, Jr., Benotti PN, Arkin CF, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112: 423-8.
51. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. Journal of Clinical Oncology 2005; 23: 4063-9.
52. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 2002; 32: 84-8.
53. Ruud E, Holmstrom H, De Lange C, Hogstad EM, Wesenberg F. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies - a randomized, controlled study. Acta Paediatr 2006; 95: 1053-9.
54. Young. WARP - A multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs) 1 June 2005; 2005 (abstr ASCO 8004).
55. Klerk CP, Smorenburg SM, Buller HR. Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review. Arch Intern Med 2003; 163: 1913-21.
56. Cunningham MS, White B, Hollywood D, O'Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters - a reappraisal of the evidence. British Journal of Cancer 2006; 94: 189-94.
57. Akl EA, Karmath G, Yosuico V, Kim SY, Barba M, Sperati F, et al. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. Cochrane Database Syst Rev 2007; CD006468.
58. Rawson KM, Newborn-Cook CV. The use of low-dose warfarin as prophylaxis for central venous catheter thrombosis in patients with cancer: a meta-analysis. Oncol Nurs Forum 2007; 34: 1037-43.
59. Kirkpatrick A, Rathbun S, Whitsett T, Raskob G. Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med 2007; 120: 901-13.
60. Carrier M, Tay J, Fergusson D, Wells PS. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 2007; 5: 2552-4
61. Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 2008; 99: 38-43.
62. Masci G, Magagnoli M, Zucali PA, Castagna L, Carnaghi C, Sarina B, et al. Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? Journal of Clinical Oncology 2003; 21: 736-9.
63. Magagnoli M, Masci G, Carnaghi C, Zucali PA, Castagna L, Morenghi E, et al. Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen. Ann Oncol 2003; 14: 959-60.
64. Magagnoli M, Masci G, Castagna L, Morenghi E, Santoro A. High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens. Ann Oncol 2006; 17: 174-6.
65. Abdelkefi A, Ben OT, Kammoun L, Chelli M, Romdhane NB, Kriaa A, et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. Thrombosis & Haemostasis 2004; 92: 654-61.
66. Karthaus M, Kretzschmar A, Kroning H, Biakhov M, Irwin D, Marschner N, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 17: 289-96.
67. Mismetti P, Mille D, Laporte S, Charlet V, Buchmuller-Cordier A, Jacquin JP, et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003; 88: 67-73.
68. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thrombosis & Haemostasis 1996; 75: 251-3.
69. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. Journal of Clinical Oncology 2005; 23: 4057-62.
70. DeCicco M, Matovic M, Pacenzia R, Fantin D, Caserta R, Bortolussi F, et al. Short-term acenocumarine (A) or dalteparine (D) for the prevention of central venous catheter-related thrombosis (CVCrT) in cancer patients. A randomized controlled study based on serial venographies. 2006 (abstr ASCO 8549).
71. Niers TM, Di NM, Klerk CP, Baarslag HJ, Buller HR, Biemond BJ. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost 2007; 5: 1878-82.
72. Kalmanti M, Germanakis J, Stiakaki E, Syfridaki C, Christidou A, Tsetis D, et al. Prophylaxis with urokinase in pediatric oncology patients with central venous catheters. Pediatric Hematology & Oncology 2002; 19: 173-9.
73. Biffi R, De BF, Orsi F, Pozzi S, Arnaldi P, Goldhirsch A, et al. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 2001; 92: 1204-12.
74. Carlo JT, Lamont JP, McCarty TM, Livingston S, Kuhn JA. A prospective randomized trial demonstrating valved implantable ports have fewer complications and lower overall cost than nonvalved implantable ports. American Journal of Surgery 2004; 188: 722-7.
75. Labourey JL, Lacroix P, Genet D, Gobeaux F, Martin J, Venat-Bouvet L, et al. Thrombotic complications of implanted central venous access devices: prospective evaluation. Bulletin du Cancer 2004; 91: 431-6.
76. Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. Journal of Clinical Oncology 2006; 24: 1404-8.
77. Luciani A, Clement O, Halimi P, Goudot D, Portier F, Bassot V, et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220: 655-60.
78. Nightingale CE, Norman A, Cunningham D, Young J, Webb A, Filshie J. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Eur J Cancer 1997; 33: 398-403.
79. Morazin F, Kriegel I, Asselain B, Falcou MC. Thrombose symptomatique sur cathéter veineux central de longue durée en oncologie: un score de risque prédictif? Revue de Medecine Interne 2005; 26: 273-9.
80. Caers J, Fontaine C, Vinh-Hung V, De MJ, Ponnet G, Oost C, et al. Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. Supportive Care in Cancer 2005; 13: 325-31.
81. Cadman A, Lawrance JA, Fitzsimmons L, Spencer-Shaw A, Swindell R. To clot or not to clot? That is the question in central venous catheters. Clin Radiol 2004; 59: 349-55.
82. Craft PS, May J, Dorigo A, Hoy C, Plant A. Hickman catheters: left-sided insertion, male gender, and obesity are associated with an increased risk of complications. Aust N Z J Med 1996; 26: 33-9.
83. Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. Journal of Clinical Oncology 1995; 13: 233-8.
84. NICE, (National Institute for Clinical excellence). Guidance on the use of ultrasound locating devices for placing central venous catheters. Technology Appraisal No. 49. [online]. 2002. Available: URL: http://www.nice.org.uk/pdf/Ultrasound_49_GUIDANCE.pdf.
85. Savage KJ, Wells PS, Schulz V, Goudie D, Morrow B, Cruickshank M, et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thrombosis & Haemostasis 1999; 82: 1008-10.
86. Rodenhuis S, van't Hek LG, Vlasveld LT, Kroger R, Dubbelman R, van Tol RG. Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator. Thorax 1993; 48: 558-9.
87. Schindler J, Bona RD, Chen HH, Feingold JM, Edwards RL, Tutschka PJ, et al. Regional thrombolysis with urokinase for central venous catheter-related thrombosis in patients undergoing high-dose chemotherapy with autologous blood stem cell rescue. Clinical & Applied Thrombosis/Hemostasis 1999; 5: 25-9.
88. Pucheu A, Dierhas M, Leduc B, Sillet-Bach I, Lefort S, Assaf W, et al. Fibrinolyse des thromboses veineuses profondes sur dispositifs de perfusion implantables. À propos d'une série consécutive de 57 thromboses et de 32 fibrinolyses. Bull Cancer 1996; 83: 293-9.
89. Frank DA, Meuse J, Hirsch D, Ibrahim JG, van den Abbeele AD. The treatment and outcome of cancer patients with thromboses on central venous catheters. Journal of Thrombosis & Thrombolysis 2000; 10: 271-5.